How do transfusion services manage patients taking therapies such as anti‐ CD38 and anti‐ CD47 known to interfere with red blood cell compatibility testing?
Background: Drugs such as daratumumab (Darzalex, anti‐CD38) and Hu5F9‐G4 (magrolimab, anti‐CD47) may interfere with red blood cell compatibility testing as CD38 and CD47 are expressed on red blood cells. Study Design and Methods: A survey of AABB member transfusion services was undertaken to underst...
| Hauptverfasser: | , , , |
|---|---|
| Format: | Journal article |
| Sprache: | English |
| Veröffentlicht: |
Wiley
2024
|